Open AccessREGEN-COV™ (Casirivimab and Imdevimab) along with Molnupiravir InStage- V CKD Patient with Symptomatic COVID-19 Pneumonia: A Case Report
Author(s) -
Mamun Mostafi,
AUTHOR_ID,
Ahammad Shamir Shawrov,
M. A. Wahab,
Abu Jafar Mohammed Saleh,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2022
Language(s) - English
DOI - 10.47363/jone/2022(2)105
Subject(s) - covid-19 , medicine , pneumonia , intensive care medicine , virology , surgery , outbreak , disease , infectious disease (medical specialty)
Combination of two human monoclonal antibodies, Casirivimab and imdevimab, commonly termed as Cocktail therapy recommended for the treatment and prevention of COVID-19. It is administered as an infusion or subcutaneous injection. Molnupiravir is an antiviral medication that inhibits the replication of certain RNA viruses. There is very limited data available regarding co administration of oral Molnupiravir along with intravenous REGEN-COV™ (Casirivimab and imdevimab) in CKD patient. Here, we report the successful outcome of REGEN-COV™ along with oral Molnupiravir in a CKD Stage V hospitalized patient with Symptomatic COVID-19 Pneumonia